{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T17:56:14Z","timestamp":1792691774715,"version":"4.5.0"},"reference-count":76,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T00:00:00Z","timestamp":1782345600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100020908","name":"Pfizer SAS","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100020908","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bulletin du Cancer"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.bulcan.2026.04.009","type":"journal-article","created":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T17:25:22Z","timestamp":1783617922000},"page":"1047-1065","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Comment pr\u00e9venir et g\u00e9rer les toxicit\u00e9s h\u00e9matologiques li\u00e9es aux inhibiteurs de PARP dans le cancer de la prostate\u00a0?"],"prefix":"10.1016","volume":"113","author":[{"given":"Oph\u00e9lie","family":"Cassuto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonin","family":"Schmitt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carole","family":"Helissey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aur\u00e9lien","family":"Gobert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Romain","family":"Mathieu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clara","family":"Bouteleux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lo\u00efc","family":"Mourey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Jovenin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florence","family":"Joly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.bulcan.2026.04.009_bib0365","doi-asserted-by":"crossref","first-page":"2","DOI":"10.3390\/life14020198","article-title":"PARP inhibitors in metastatic castration-resistant prostate cancer: unraveling the therapeutic landscape","volume":"14","author":"Al-Akhras","year":"2024","journal-title":"Life"},{"issue":"6","key":"10.1016\/j.bulcan.2026.04.009_bib0370","doi-asserted-by":"crossref","first-page":"6","DOI":"10.3390\/biomedicines10061416","article-title":"PARP inhibitors: a new horizon for patients with prostate cancer","volume":"10","author":"Congregado","year":"2022","journal-title":"Biomedicines"},{"issue":"15","key":"10.1016\/j.bulcan.2026.04.009_bib0375","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1016\/j.purol.2022.07.147","article-title":"French AFU cancer committee guidelines\u00a0\u2013\u00a0update 2022\u20132024: prostate cancer\u00a0\u2013\u00a0management of metastatic disease and castration resistance","volume":"32","author":"Ploussard","year":"2022","journal-title":"Prog Urol"},{"issue":"1","key":"10.1016\/j.bulcan.2026.04.009_bib0380","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.bulcan.2024.05.008","article-title":"Cancer de prostate m\u00e9tastatique r\u00e9sistant \u00e0 la castration et inhibiteurs de PARP\u00a0: de la g\u00e9nomique tumorale aux nouvelles associations th\u00e9rapeutiques","volume":"112","author":"Oudard","year":"2025","journal-title":"Bull Cancer"},{"issue":"9","key":"10.1016\/j.bulcan.2026.04.009_bib0385","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1093\/annonc\/mdz192","article-title":"A decade of clinical development of PARP inhibitors in perspective","volume":"30","author":"Mateo","year":"2019","journal-title":"Ann Oncol"},{"issue":"3","key":"10.1016\/j.bulcan.2026.04.009_bib0390","doi-asserted-by":"crossref","first-page":"801","DOI":"10.3390\/cancers14030801","article-title":"Co-inhibition of androgen receptor and PARP as a novel treatment paradigm in prostate cancer\u00a0\u2013\u00a0where are we now?","volume":"14","author":"Rao","year":"2022","journal-title":"Cancers"},{"issue":"10","key":"10.1016\/j.bulcan.2026.04.009_bib0395","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1016\/S1470-2045(23)00382-0","article-title":"Olaparib plus abiraterone versus placebo plus abiraterone in metastatic castration-resistant prostate cancer (PROpel): final prespecified overall survival results of a randomised, double-blind, phase 3\u00a0trial","volume":"24","author":"Saad","year":"2023","journal-title":"Lancet Oncol"},{"issue":"6_suppl","key":"10.1016\/j.bulcan.2026.04.009_bib0400","doi-asserted-by":"crossref","first-page":"LBA16","DOI":"10.1200\/JCO.2023.41.6_suppl.LBA16","article-title":"Final overall survival (OS) in PROpel: abiraterone (abi) and olaparib (ola) versus abiraterone and placebo (pbo) as first-line (1L) therapy for metastatic castration-resistant prostate cancer (mCRPC)","volume":"41","author":"Clarke","year":"2023","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.bulcan.2026.04.009_bib0405","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1111\/bju.16130","article-title":"Poly(adenosine diphosphate-ribose) polymerase inhibitor combinations in first-line metastatic castrate-resistant prostate cancer setting: a systematic review and meta-analysis","volume":"132","author":"Sayyid","year":"2023","journal-title":"BJU Int"},{"issue":"10502","key":"10.1016\/j.bulcan.2026.04.009_bib0410","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/S0140-6736(25)00683-X","article-title":"Talazoparib plus enzalutamide in men with HRR-deficient metastatic castration-resistant prostate cancer: final overall survival results from the randomised, placebo-controlled, phase 3\u00a0TALAPRO-2\u00a0trial","volume":"406","author":"Fizazi","year":"2025","journal-title":"Lancet"},{"issue":"17_suppl","key":"10.1016\/j.bulcan.2026.04.009_bib0415","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2025.43.17_suppl.LBA5006","article-title":"Phase 3\u00a0AMPLITUDE trial: niraparib (NIRA) and abiraterone acetate plus prednisone (AAP) for metastatic castration-sensitive prostate cancer (mCSPC) patients (pts) with alterations in homologous recombination repair (HRR) genes","volume":"43","author":"Attard","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bulcan.2026.04.009_bib0420","unstructured":"EMA. LYNPARZA (olaparib)\u00a0\u2013\u00a0RCP [Internet]. [cit\u00e9 26\u00a0juin 2024]. Disponible sur\u00a0: https:\/\/www.ema.europa.eu\/fr\/documents\/product-information\/lynparza-epar-product-information_fr.pdf."},{"key":"10.1016\/j.bulcan.2026.04.009_bib0425","unstructured":"L\u00e9gifrance. Arr\u00eat\u00e9 du 20\u00a0septembre 2024\u00a0modifiant la liste des sp\u00e9cialit\u00e9s pharmaceutiques remboursables aux assur\u00e9s sociaux\u00a0\u2013\u00a0LYNPARZA. Journal officiel\u00a0\u2013\u00a0JORF no\u00a00227\u00a0du 24\/09\/2024 [Internet]. [cit\u00e9 16\u00a0sept 2025]. Disponible sur\u00a0: https:\/\/www.legifrance.gouv.fr\/download\/pdf?id=g4kAqhInN7cYVepX3f55N_j-ISq88PA6yoPhkTVJ7BU=."},{"key":"10.1016\/j.bulcan.2026.04.009_bib0430","unstructured":"L\u00e9gifrance. Arr\u00eat\u00e9 du 4\u00a0novembre 2022\u00a0modifiant la liste des sp\u00e9cialit\u00e9s pharmaceutiques agr\u00e9\u00e9es \u00e0 l\u2019usage des collectivit\u00e9s et divers services publics\u00a0\u2013\u00a0LYNPARZA [Internet]. [cit\u00e9 1\u00a0oct 2025]. Disponible sur\u00a0: https:\/\/www.legifrance.gouv.fr\/jorf\/id\/JORFTEXT000046534259."},{"key":"10.1016\/j.bulcan.2026.04.009_bib0435","unstructured":"EMA. TALZENNA (talazoparib)\u00a0\u2013\u00a0RCP [Internet]. [cit\u00e9 26\u00a0juin 2024]. Disponible sur\u00a0: https:\/\/www.ema.europa.eu\/fr\/documents\/product-information\/talzenna-epar-product-information_fr.pdf."},{"key":"10.1016\/j.bulcan.2026.04.009_bib0440","unstructured":"L\u00e9gifrance. Arr\u00eat\u00e9 du 3\u00a0f\u00e9vrier 2025\u00a0modifiant la liste des sp\u00e9cialit\u00e9s pharmaceutiques remboursables aux assur\u00e9s sociaux\u00a0\u2013\u00a0TALZENNA. Journal officiel\u00a0\u2013\u00a0JORF no\u00a00031\u00a0du 06\/02\/2025 [Internet]. [cit\u00e9 16\u00a0sept 2025]. Disponible sur\u00a0: https:\/\/www.legifrance.gouv.fr\/download\/pdf?id=0HPHOR5ON1VxAQ7joozNhiBTeN2gKVrvqLBncL23CaI=."},{"key":"10.1016\/j.bulcan.2026.04.009_bib0445","unstructured":"EMA. AKEEGA (niraparib\/ac\u00e9tate d\u2019abirat\u00e9rone)\u00a0\u2013\u00a0RCP [Internet]. [cit\u00e9 26\u00a0juin 2024]. Disponible sur\u00a0: https:\/\/www.ema.europa.eu\/fr\/documents\/product-information\/akeega-epar-product-information_fr.pdf."},{"issue":"25","key":"10.1016\/j.bulcan.2026.04.009_bib0450","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1056\/NEJMoa1910962","article-title":"Niraparib in patients with newly diagnosed advanced ovarian cancer","volume":"381","author":"Gonz\u00e1lez-Mart\u00edn","year":"2019","journal-title":"N Engl J Med"},{"issue":"9737","key":"10.1016\/j.bulcan.2026.04.009_bib0455","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/S0140-6736(10)60893-8","article-title":"Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1\u00a0or BRCA2\u00a0mutations and recurrent ovarian cancer: a proof-of-concept trial","volume":"376","author":"Audeh","year":"2010","journal-title":"Lancet"},{"issue":"16_suppl","key":"10.1016\/j.bulcan.2026.04.009_bib0460","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2023.41.16_suppl.5053","article-title":"Talazoparib (TALA) plus enzalutamide (ENZA) in metastatic castration-resistant prostate cancer (mCRPC): safety analyses from the randomized, placebo (PBO)-controlled, phase 3\u00a0TALAPRO-2\u00a0study","volume":"41","author":"Azad","year":"2023","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.bulcan.2026.04.009_bib0465","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1111\/jcpt.13349","article-title":"Haematologic toxicities with PARP inhibitors in cancer patients: an up-to-date meta-analysis of 29\u00a0randomized controlled trials","volume":"46","author":"Wang","year":"2021","journal-title":"J Clin Pharm Ther"},{"key":"10.1016\/j.bulcan.2026.04.009_bib0470","doi-asserted-by":"crossref","first-page":"3009","DOI":"10.2147\/DDDT.S147726","article-title":"Risk of severe hematologic toxicities in cancer patients treated with PARP inhibitors: a meta-analysis of randomized controlled trials","volume":"11","author":"Zhou","year":"2017","journal-title":"Drug Des Devel Ther"},{"issue":"19","key":"10.1016\/j.bulcan.2026.04.009_bib0475","doi-asserted-by":"crossref","first-page":"4904","DOI":"10.3390\/cancers15194904","article-title":"Hematological toxicities with PARP inhibitors in prostate cancer: a systematic review and meta-analysis of phase II\/III randomized controlled trials","volume":"15","author":"Bowling","year":"2023","journal-title":"Cancers"},{"key":"10.1016\/j.bulcan.2026.04.009_bib0480","series-title":"Common Terminology Criteria for Adverse Events (CTCAE) version 5. 0","year":"2017"},{"issue":"9","key":"10.1016\/j.bulcan.2026.04.009_bib0485","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1093\/oncolo\/oyad045","article-title":"Real-world treatment trends among patients with metastatic castration-sensitive prostate cancer: results from an international study","volume":"28","author":"Barata","year":"2023","journal-title":"Oncologist"},{"issue":"12","key":"10.1016\/j.bulcan.2026.04.009_bib0490","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1016\/j.bulcan.2022.06.011","article-title":"Gestion pratique des inhibiteurs de PARP\u00a0: un consensus national DELPHI","volume":"109","author":"Selle","year":"2022","journal-title":"Bull Cancer"},{"issue":"24","key":"10.1016\/j.bulcan.2026.04.009_bib0495","doi-asserted-by":"crossref","first-page":"2345","DOI":"10.1056\/NEJMoa2022485","article-title":"Survival with olaparib in metastatic castration-resistant prostate cancer","volume":"383","author":"Hussain","year":"2020","journal-title":"N Engl J Med"},{"issue":"32","key":"10.1016\/j.bulcan.2026.04.009_bib0500","doi-asserted-by":"crossref","first-page":"3763","DOI":"10.1200\/JCO.20.01035","article-title":"Rucaparib in men with metastatic castration-resistant prostate cancer harboring a BRCA1\u00a0or BRCA2\u00a0gene alteration","volume":"38","author":"Abida","year":"2020","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.bulcan.2026.04.009_bib0505","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/S1470-2045(21)00757-9","article-title":"Niraparib in patients with metastatic castration-resistant prostate cancer and DNA repair gene defects (GALAHAD): a multicentre, open-label, phase 2\u00a0trial","volume":"23","author":"Smith","year":"2022","journal-title":"Lancet Oncol"},{"issue":"9","key":"10.1016\/j.bulcan.2026.04.009_bib0510","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1016\/S1470-2045(21)00376-4","article-title":"Talazoparib monotherapy in metastatic castration-resistant prostate cancer with DNA repair alterations (TALAPRO-1): an open-label, phase 2\u00a0trial","volume":"22","author":"de Bono","year":"2021","journal-title":"Lancet Oncol"},{"issue":"18","key":"10.1016\/j.bulcan.2026.04.009_bib0515","doi-asserted-by":"crossref","first-page":"3339","DOI":"10.1200\/JCO.22.01649","article-title":"Niraparib and abiraterone acetate for metastatic castration-resistant prostate cancer","volume":"41","author":"Chi","year":"2023","journal-title":"J Clin Oncol"},{"issue":"10398","key":"10.1016\/j.bulcan.2026.04.009_bib0520","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/S0140-6736(23)01055-3","article-title":"Talazoparib plus enzalutamide in men with first-line metastatic castration-resistant prostate cancer (TALAPRO-2): a randomised, placebo-controlled, phase 3\u00a0trial","volume":"402","author":"Agarwal","year":"2023","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.bulcan.2026.04.009_bib0525","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11523-023-01016-x","article-title":"Hematological toxicity of PARP inhibitors in metastatic prostate cancer patients with mutations of BRCA or HRR genes: a systematic review and safety meta-analysis","volume":"19","author":"Maiorano","year":"2024","journal-title":"Target Oncol"},{"issue":"3","key":"10.1016\/j.bulcan.2026.04.009_bib0530","doi-asserted-by":"crossref","first-page":"3365","DOI":"10.1002\/cam4.5062","article-title":"Hematological toxicities in PARP inhibitors: a real-world study using FDA adverse event reporting system (FAERS) database","volume":"12","author":"Shu","year":"2023","journal-title":"Cancer Med"},{"key":"10.1016\/j.bulcan.2026.04.009_bib0535","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.ejca.2022.04.016","article-title":"Olaparib tolerability and common adverse-event management in patients with metastatic castration-resistant prostate cancer: further analyses from the PROfound study","volume":"170","author":"Roubaud","year":"2022","journal-title":"Eur J Cancer"},{"issue":"6","key":"10.1016\/j.bulcan.2026.04.009_bib0540","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1016\/j.euo.2024.03.006","article-title":"Tolerability of olaparib combined with abiraterone in patients with metastatic castration-resistant prostate cancer: further results from the phase 3\u00a0PROpel trial","volume":"7","author":"Saad","year":"2024","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.bulcan.2026.04.009_bib0545","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2024.115078","article-title":"Talazoparib plus enzalutamide in metastatic castration-resistant prostate cancer: safety analyses from the randomized, placebo-controlled, phase III TALAPRO-2\u00a0study","volume":"213","author":"Azad","year":"2024","journal-title":"Eur J Cancer"},{"issue":"10502","key":"10.1016\/j.bulcan.2026.04.009_bib0550","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/S0140-6736(25)00684-1","article-title":"Talazoparib plus enzalutamide in men with metastatic castration-resistant prostate cancer: final overall survival results from the randomised, placebo-controlled, phase 3\u00a0TALAPRO-2\u00a0trial","volume":"406","author":"Agarwal","year":"2025","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.bulcan.2026.04.009_bib0555","doi-asserted-by":"crossref","first-page":"e122","DOI":"10.1016\/S2352-3026(20)30360-4","article-title":"Myelodysplastic syndrome and acute myeloid leukaemia in patients treated with PARP inhibitors: a safety meta-analysis of randomised controlled trials and a retrospective study of the WHO pharmacovigilance database","volume":"8","author":"Morice","year":"2021","journal-title":"Lancet Haematol"},{"issue":"3","key":"10.1016\/j.bulcan.2026.04.009_bib0560","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/j.ygyno.2021.03.011","article-title":"Incidence of myelodysplastic syndrome and acute myeloid leukemia in patients receiving poly-ADP ribose polymerase inhibitors for the treatment of solid tumors: a meta-analysis of randomized trials","volume":"161","author":"Nitecki","year":"2021","journal-title":"Gynecol Oncol"},{"issue":"7","key":"10.1016\/j.bulcan.2026.04.009_bib0565","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1038\/s41375-022-01613-1","article-title":"The 5th edition of the World Health Organization classification of haematolymphoid tumours: myeloid and histiocytic\/dendritic neoplasms","volume":"36","author":"Khoury","year":"2022","journal-title":"Leukemia"},{"key":"10.1016\/j.bulcan.2026.04.009_bib0570","doi-asserted-by":"crossref","DOI":"10.1177\/17588359241248328","article-title":"Improving olaparib exposure to optimize adverse effects management","volume":"16","author":"Sterl\u00e9","year":"2024","journal-title":"Ther Adv Med Oncol"},{"key":"10.1016\/j.bulcan.2026.04.009_bib0575","doi-asserted-by":"crossref","first-page":"S992","DOI":"10.1016\/j.annonc.2023.09.2782","article-title":"1834P Exposure-efficacy analyses of talazoparib in combination with enzalutamide in patients with metastatic castration-resistant prostate cancer (mCRPC) in the TALAPRO-2\u00a0trial","volume":"34","author":"Azad","year":"2023","journal-title":"Ann Oncol"},{"key":"10.1016\/j.bulcan.2026.04.009_bib0580","doi-asserted-by":"crossref","first-page":"S990","DOI":"10.1016\/j.annonc.2023.09.2777","article-title":"1829P Exposure-safety analyses of talazoparib in combination of enzalutamide in patients with metastatic castration-resistant prostate cancer (mCRPC) in TALAPRO-2\u00a0trial","volume":"34","author":"Azad","year":"2023","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.bulcan.2026.04.009_bib0585","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1038\/s41591-023-02704-x","article-title":"First-line talazoparib with enzalutamide in HRR-deficient metastatic castration-resistant prostate cancer: the phase 3\u00a0TALAPRO-2\u00a0trial","volume":"30","author":"Fizazi","year":"2024","journal-title":"Nat Med"},{"key":"10.1016\/j.bulcan.2026.04.009_bib0590","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/S2666-1683(24)01230-8","article-title":"P103\u00a0assessment of the impact of talazoparib dose reductions on the efficacy of combined talazoparib and enzalutamide treatment in patients with metastatic Castrate Resistant Prostate Cancer (mCRPC) in the TALAPRO-2 (TP-2) study","volume":"69","author":"Giorgi","year":"2024","journal-title":"Eur Urol Open Sci"},{"issue":"12","key":"10.1016\/j.bulcan.2026.04.009_bib0595","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1007\/s40262-022-01167-6","article-title":"Pharmacokinetics and pharmacodynamics of PARP inhibitors in oncology","volume":"61","author":"Bruin","year":"2022","journal-title":"Clin Pharmacokinet"},{"issue":"1","key":"10.1016\/j.bulcan.2026.04.009_bib0600","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1182\/blood-2012-12-472845","article-title":"Parp-2\u00a0is required to maintain hematopoiesis following sublethal \u03b3-irradiation in mice","volume":"122","author":"Farr\u00e9s","year":"2013","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.bulcan.2026.04.009_bib0605","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1038\/cdd.2014.202","article-title":"PARP-2\u00a0sustains erythropoiesis in mice by limiting replicative stress in erythroid progenitors","volume":"22","author":"Farr\u00e9s","year":"2015","journal-title":"Cell Death Differ"},{"issue":"1","key":"10.1016\/j.bulcan.2026.04.009_bib0610","doi-asserted-by":"crossref","first-page":"1","DOI":"10.5430\/crim.v6n1p1","article-title":"Severe folate deficiency anemia associated with the use of a PARP inhibitor (olaparib) in a patient with fallopian tube cancer","volume":"6","author":"Yohannan","year":"2018","journal-title":"CRIM"},{"issue":"13","key":"10.1016\/j.bulcan.2026.04.009_bib0615","doi-asserted-by":"crossref","first-page":"8621","DOI":"10.1074\/jbc.M807198200","article-title":"Poly(ADP-ribose) polymerase 1\u00a0interacts with Nuclear Respiratory Factor 1 (NRF-1) and plays a role in NRF-1\u00a0transcriptional regulation","volume":"284","author":"Hossain","year":"2009","journal-title":"J Biol Chem"},{"issue":"2","key":"10.1016\/j.bulcan.2026.04.009_bib0620","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1158\/1541-7786.MCR-18-0138","article-title":"PARP1\u00a0trapping by PARP inhibitors drives cytotoxicity in both cancer cells and healthy bone marrow","volume":"17","author":"Hopkins","year":"2019","journal-title":"Mol Cancer Res"},{"issue":"13_Supplement","key":"10.1016\/j.bulcan.2026.04.009_bib0625","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.AM2018-LB-273","article-title":"Abstract LB-273: a head-to-head comparison of the properties of five clinical PARP inhibitors identifies new insights that can explain both the observed clinical efficacy and safety profiles","volume":"78","author":"Leo","year":"2018","journal-title":"Cancer Res"},{"issue":"11","key":"10.1016\/j.bulcan.2026.04.009_bib0630","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1016\/j.bulcan.2023.02.022","article-title":"Therapy-related myelodysplastic syndromes in the genomics era","volume":"110","author":"Renneville","year":"2023","journal-title":"Bull Cancer"},{"issue":"10","key":"10.1016\/j.bulcan.2026.04.009_bib0635","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1016\/j.revmed.2019.05.005","article-title":"L\u2019h\u00e9matopo\u00ef\u00e8se clonale\u00a0: un concept \u00e9mergent \u00e0 la crois\u00e9e des sp\u00e9cialit\u00e9s","volume":"40","author":"Danlos","year":"2019","journal-title":"Rev Med Interne"},{"key":"10.1016\/j.bulcan.2026.04.009_bib0640","doi-asserted-by":"crossref","DOI":"10.1177\/17588359251367308","article-title":"Prevention and management of PARP inhibitor-related haematological toxicities in prostate cancer: French expert opinion using the Delphi method","volume":"17","author":"Cassuto","year":"2025","journal-title":"Ther Adv Med Oncol"},{"issue":"5","key":"10.1016\/j.bulcan.2026.04.009_bib0645","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1111\/ejh.13595","article-title":"The incidence of thrombocytopenia in adult patients receiving chemotherapy for solid tumors or hematologic malignancies","volume":"106","author":"Shaw","year":"2021","journal-title":"Eur J Haematol"},{"issue":"1","key":"10.1016\/j.bulcan.2026.04.009_bib0650","first-page":"1","article-title":"Anemia in men with advanced prostate cancer: incidence, etiology, and treatment","volume":"6","author":"Nalesnik","year":"2004","journal-title":"Rev Urol"},{"issue":"6_suppl","key":"10.1016\/j.bulcan.2026.04.009_bib0655","article-title":"TALAPRO-2: phase 3\u00a0study of talazoparib (TALA)+enzalutamide (ENZA) versus placebo (PBO)+ENZA as first-line (1L) treatment in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)","volume":"41","author":"Agarwal","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bulcan.2026.04.009_bib0660","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.euros.2024.12.008","article-title":"Incidence and risk of thromboembolic and cardiovascular adverse events with PARP inhibitor treatment in patients with metastatic castration-resistant prostate cancer: a systematic review and safety meta-analysis","volume":"72","author":"Maiorano","year":"2025","journal-title":"Eur Urol Open Sci"},{"key":"10.1016\/j.bulcan.2026.04.009_bib0665","doi-asserted-by":"crossref","first-page":"S242","DOI":"10.1016\/j.thromres.2018.02.132","article-title":"The action of erythropoietin on venous thromboembolic events in lung cancer patients","volume":"164","author":"Dimakakos","year":"2018","journal-title":"Thromb Res"},{"issue":"12","key":"10.1016\/j.bulcan.2026.04.009_bib0670","doi-asserted-by":"crossref","first-page":"e115060","DOI":"10.1371\/journal.pone.0115060","article-title":"Screening for vulnerability in older cancer patients: the ONCODAGE prospective multicenter cohort study","volume":"9","author":"Soubeyran","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.bulcan.2026.04.009_bib0675","series-title":"La conciliation des traitements m\u00e9dicamenteux en canc\u00e9rologie","year":"2019"},{"key":"10.1016\/j.bulcan.2026.04.009_bib0680","series-title":"An\u00e9mie et cancer","year":"2021"},{"key":"10.1016\/j.bulcan.2026.04.009_bib0685","unstructured":"Haute Autorit\u00e9 de sant\u00e9. [cit\u00e9 22\u00a0mai 2025]. Transfusions de globules rouges homologues\u00a0: produits, indications, alternatives. Disponible sur\u00a0: https:\/\/www.has-sante.fr\/jcms\/c_1349939\/fr\/transfusions-de-globules-rouges-homologues-produits-indications-alternatives."},{"key":"10.1016\/j.bulcan.2026.04.009_bib0690","unstructured":"Haute Autorit\u00e9 de sant\u00e9. [cit\u00e9 22\u00a0mai 2025]. An\u00e9mie chez l\u2019insuffisant r\u00e9nal\u00a0: comment utiliser les agents stimulant l\u2019\u00e9rythropo\u00ef\u00e8se. Disponible sur\u00a0: https:\/\/www.has-sante.fr\/jcms\/c_1647165\/fr\/anemie-chez-l-insuffisant-renal-comment-utiliser-les-agents-stimulant-l-erythropoiese."},{"issue":"1","key":"10.1016\/j.bulcan.2026.04.009_bib0695","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.ejca.2010.10.013","article-title":"2010\u00a0update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours","volume":"47","author":"Aapro","year":"2011","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.bulcan.2026.04.009_bib0700","unstructured":"Oncolink [Internet]. [cit\u00e9 19\u00a0sept 2025]. Onco\u2019Link\u00a0\u2013\u00a0th\u00e9rapies orales. Disponible sur\u00a0: https:\/\/therapiesorales-onco-link.fr\/."},{"key":"10.1016\/j.bulcan.2026.04.009_bib0705","unstructured":"Gestion en pratique courante des iPARP [Internet]. [cit\u00e9 19\u00a0sept 2025]. Disponible sur\u00a0: https:\/\/medical.gsk.com\/fr-fr\/oncologie\/programmes-educationnels\/iparp-module-formation\/."},{"key":"10.1016\/j.bulcan.2026.04.009_bib0710","unstructured":"Haute Autorit\u00e9 de sant\u00e9. [cit\u00e9 22\u00a0mai 2025]. CUREETY TECHCARE. Disponible sur\u00a0: https:\/\/www.has-sante.fr\/jcms\/p_3455755\/fr\/cureety-techcare."},{"key":"10.1016\/j.bulcan.2026.04.009_bib0715","unstructured":"Haute Autorit\u00e9 de sant\u00e9. [cit\u00e9 22\u00a0mai 2025]. RESILIENCE PRO. Disponible sur\u00a0: https:\/\/www.has-sante.fr\/jcms\/p_3470263\/fr\/resilience-pro."},{"key":"10.1016\/j.bulcan.2026.04.009_bib0720","doi-asserted-by":"crossref","first-page":"1104700","DOI":"10.3389\/fdgth.2023.1104700","article-title":"Effectiveness of electronic patient reporting outcomes, by a digital telemonitoring platform, for prostate cancer care: the Protecty study","volume":"5","author":"Helissey","year":"2023","journal-title":"Front Digit Health"},{"key":"10.1016\/j.bulcan.2026.04.009_bib721","doi-asserted-by":"crossref","unstructured":"Bryce AH, Piulats JM, Reaume MN, Ostler PJ, McDermott RS, Gingerich JR, et al. Rucaparib for metastatic castration-resistant prostate cancer (mCRPC): TRITON3 interim overall survival and efficacy of rucaparib vs docetaxel or second-generation androgen pathway inhibitor therapy. JCO. 20 f\u00e9vr 2023;41(6_suppl):18\u201118.","DOI":"10.1200\/JCO.2023.41.6_suppl.18"},{"key":"10.1016\/j.bulcan.2026.04.009_bib722","doi-asserted-by":"crossref","unstructured":"Fizazi K, Piulats JM, Reaume MN, Ostler P, McDermott R, Gingerich JR, et al. Rucaparib or Physician's Choice in Metastatic Prostate Cancer. New England Journal of Medicine. 22 f\u00e9vr 2023;388(8):719\u201132. doi:10.1056\/NEJMoa2214676","DOI":"10.1056\/NEJMoa2214676"},{"issue":"4","key":"10.1016\/j.bulcan.2026.04.009_bib723","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1016\/j.euo.2025.04.012","article-title":"Niraparib and Abiraterone Acetate plus Prednisone in Metastatic Castration-resistant Prostate Cancer: Final Overall Survival Analysis for the Phase 3 MAGNITUDE Trial","volume":"8","author":"Chi","year":"2025","journal-title":"Eur Urol Oncol. ao\u00fbt"},{"key":"10.1016\/j.bulcan.2026.04.009_bib724","unstructured":"SFPO - Soci\u00e9t\u00e9 Fran\u00e7aise de Pharmacie Oncologique. NIRAPARIB - ZEJULA [Internet]. [cit\u00e9 3 nov 2025]. Disponible sur: https:\/\/oncolien.sfpo.com\/oncolien\/niraparib-zejula"}],"container-title":["Bulletin du Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0007455126003103?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0007455126003103?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T12:57:21Z","timestamp":1787230641000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0007455126003103"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":76,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S0007455126003103"],"URL":"https:\/\/doi.org\/10.1016\/j.bulcan.2026.04.009","relation":{},"ISSN":["0007-4551"],"issn-type":[{"value":"0007-4551","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comment pr\u00e9venir et g\u00e9rer les toxicit\u00e9s h\u00e9matologiques li\u00e9es aux inhibiteurs de PARP dans le cancer de la prostate\u00a0?","name":"articletitle","label":"Article Title"},{"value":"Bulletin du Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bulcan.2026.04.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Soci\u00e9t\u00e9 Fran\u00e7aise du Cancer. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}]}}